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Background. The natural cytotoxicity receptors (NCR) are important to stimulate the activity of Natural Killer (NK) cells against
transformed cells. Identification of NCR ligands and their level of expression on normal and neoplastic cells has important
implications for the rational design of immunotherapy strategies for cancer. Methodology/Principal Findings. Here we
analyze the expression of NKp30 ligand and NKp44 ligand on 30 transformed or non-transformed cell lines of different origin.
We find intracellular and surface expression of these two ligands on almost all cell lines tested. Expression of NKp30 and NKp44
ligands was variable and did not correlate with the origin of the cell line. Expression of NKp30 and NKp44 ligand correlated
with NKp30 and NKp44-mediated NK cell lysis of tumor cells, respectively. The surface expression of NKp30 ligand and NKp44
ligand was sensitive to trypsin treatment and was reduced in cells arrested in G2/M phase. Conclusion/Significance. These
data demonstrate the ubiquitous expression of the ligands for NKp30 and NKp44 and give an important insight into the
regulation of these ligands.
Citation: Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C (2007) Expression Analysis of the Ligands for the Natural Killer Cell Receptors NKp30
and NKp44. PLoS ONE 2(12): e1339. doi:10.1371/journal.pone.0001339
INTRODUCTION
Natural Killer (NK) cells represent a unique subset of lymphocytes
that can mediate innate immune responses against tumors and
certain pathogens [1–3]. Many studies have demonstrated the
effectiveness of NK cells to attack tumor cell lines or freshly
isolated primary tumor cells in vitro [4]. In murine models, NK cell
activity is important in the immune reaction against transplanted
or induced tumors in vivo [5,6]. In humans, recent studies with
patients receiving hematopoietic stem cell transplantation demon-
strated an important role of NK cells for eradicating certain types
of hematopoietic tumors [7]. This potent anti-tumor activity of
NK cells is regulated by the engagement of NK cell surface
receptors, cytokines and the crosstalk with other immune cells [8–
10]. NK cell receptors can roughly be divided into inhibitory and
activating receptors. Many inhibitory receptors recognize certain
MHC class I alleles and thereby ensure the tolerance of NK cells
against self [11]. However, also non-MHC class I recognizing
inhibitory receptors seem to be important for regulating NK cell
activity [12]. Activating receptors on human NK cells include
CD16, NKG2D, the natural cytotoxicity receptors (NCR) NKp30,
NKp44 and NKp46, DNAM-1, 2B4 (CD244), NTB-A, CRACC
(CS1) and NKp80 [13]. In recent years, most of the ligands
recognized by these receptors have been identified.
The NCR have been shown to be important receptors for the
stimulation of anti-tumor activity of human NK cells [3]. Anti-
NCR monoclonal antibodies can block NK cell-mediated lysis of
many different tumor cell lines [14–17] and the NK cell-mediated
surveillance of mitotic cells [18]. NKp30 is also involved in the
crosstalk between NK cells and dendritic cells [19]. Furthermore,
the expression of NCR on NK cell clones correlates with their
ability to lyse tumor cells [17]. This indirectly demonstrates that
ligands for NCR are expressed by many transformed, but also by
normal cells. However, the identity of the NCR ligands is still
unknown to date. Pathogen-derived structures have been shown to
interact with NCR. The hemagglutinin protein of several viruses
can bind and activate NKp46 and NKp44 [20,21]. The pp65
protein of HCMV has been shown to bind NKp30 and inhibit its
function [22]. The Plasmodium falciparum erythrocyte membrane
protein-1 is involved in the NCR-mediated NK cell attack against
infected erythrocytes [23]. Pathogens such as vaccinia virus, HIV
or herpes simplex virus have also been shown to up-regulate the
expression of cellular NCR ligands in infected cells [24–26].
Heparan sulfate structures have been postulated as cellular ligands
for NCR but functional consequences for these interactions are
debated [27–29].
A direct probe for the expression of NCR ligands is the use of
soluble NCR fusion proteins as staining reagents. Such approaches
have shown the existence of NCR ligands on several tumor cell
lines [30,31]. Here we perform an analysis of the expression of
NKp30 ligand (NKp30L) and NKp44 ligand (NKp44L) on a panel
of 30 cell lines of different origin. We demonstrate that NKp30L
and NKp44L are ubiquitously and variably expressed on
transformed and non-transformed cell lines. The surface expres-
sion of NKp30L and NKp44L correlates with sensitivity towards
NK cell lysis, is sensitive to trypsin treatment and is down-
modulated in cells arrested in G2/M phase.
RESULTS
For the intracellular detection of NCR ligands, we initially made
use of NCR-Ig fusion proteins. With these reagents we stained 11
tumor cell lines of different origin (Table 1). We obtained specific
staining of intracellular structures in all cell lines tested. As
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PLoS ONE | www.plosone.org 1 December 2007 | Issue 12 | e1339representative examples, HT-29, CHO, Jurkat and HeLa cells are
shown in Fig. 1. Interestingly, the staining pattern of the three
different NCR-Ig fusion proteins was specific and reproducible in
the different cell lines tested. The comparison with parallel
cytospin stainings using antibodies against the ER marker
calnexin, the Golgi marker GM130, the endosomal marker
EEA-1, and the late endosomal marker LAMP-1, respectively,
revealed i) that NKp46-Ig labels the ER and a subset of early
endosomes of HeLa cells, ii) that NKp44-Ig appeared to label late
endosomes in a very homogenous fashion, and iii) that NKp30-Ig
weakly stained the ER and strongly labeled a heterogenous
population of large peripheral vesicles which probably represent
early endosomal compartments (Fig. 1D). These findings suggest
that recognition structures for the three NCR are readily
detectable in all cells tested.
To directly test for the presence of NCR ligands on the surface
of cells, we used the extracellular domain of NKp30, NKp44 and
NKp46 and fused it to an aminoterminal isoleucin-zipper (ILZ)
sequence, which induces trimerization [32]. In contrast to Ig
fusion proteins, the ILZ fusion proteins show higher avidity for
surface staining and do not bind to Fc receptors [32]. The NCR-
ILZ fusion proteins were produced in the human cell line 293T,
purified and used for the staining of 30 cell lines of different origin
(Table 2). Binding of the NCR-ILZ was detected by a monoclonal
anti-ILZ antibody and analyzed by FACS. As a control, we used a
Figure 1. Immunoperoxidase stainings of acetone-fixed tumor cells on cytospins. Intracellular compartments of HT-29, 1106mel, Jurkat (A–C) and
HeLa cells (D) were stained with NKp46-Ig, NKp44-Ig and NKp30-Ig fusion proteins as indicated. In (D), intracellular stainings of HeLa cells with the ER
marker calnexin, the Golgi marker GM130, the early endosome marker EEA-1, and the late endosome marker LAMP-1 were performed in parallel for





293T Embryonic kidney cell line
A125 Lung adenocarcinoma cell line
A549 Lung adenocarcinoma cell line
1106mel Melanoma cell line
ZKR Melanoma cell line
HeLa Cervix carcinoma cell line
HT-29 Colon carcinoma cell line
LoVo Colon carcinoma cell line
BJAB B-cell lymphoma
Jurkat T-cell lymphoma
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PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1339CS1-ILZ fusion protein, which only showed background staining
on the cells tested (Fig. 2 and data not shown). An example for the
surface staining of NKp30-ILZ and NKp44-ILZ is shown in Fig. 2.
We did not observe any significant staining of NKp46-ILZ. A
possible explanation for this lack of activity could be that the ILZ
part obscures the D2 domain of NKp46, which is important for
ligand binding [30]. We therefore analyzed the expression of
NKp30L and NKp44L on the different cell lines. To make the
results between the different experiments comparable, we
normalized all FACS results to the CS1-ILZ background staining.
Most cell lines were tested between four and six times for the
expression of NKp30L and NKp44L in independent experiments.
First we analyzed seven tumor cell lines derived from pancreatic
cancer (Fig. 3A). The expression of NKp30L and NKp44L was
very variable, ranging from no detectable expression to significant
surface expression. NKp44L staining was consistently higher than
NKp30L. This could indicate, that the expression of NKp44L is
higher than that of NKp30L. However, this could also be caused
by better staining efficiency or higher affinity binding of the
NKp44-ILZ. Interestingly, the staining intensities for NKp30L
and NKp44L seemed to be linked with cells expressing high
amounts of NKp30L also expressing high amounts of NKp44L.
This variable but linked expression was also observed in four
different breast carcinoma cell lines tested (Fig. 3B).
When we extended our analysis to more tumor cell lines of
different origin we detected NKp30L and NKp44L on the surface
of almost all cell lines tested (Fig. 4A). This indicates that the
ligands for NKp30 and NKp44 are widely expressed on tumor
cells, consistent with the finding that these NK cell receptors are
involved in the lysis of many different tumors. However, not only
transformed cells showed expression of NKp30L and NKp44L.
We could also detect the presence of NKp30L and NKp44L on
primary human foreskin fibroblasts and found NKp44L even on
murine primary osteoblasts (Fig. 4A). NK cells are particularly
effective in attacking hematological malignancies. Interestingly,
when testing cell lines of hematological origin, we detected much
lesssurfacestainingofNKp30LandNKp44Lwhencomparedtothe
solid tumors tested (Fig. 4B). Also, the staining of NKp30L and
NKp44L was not linked in these tumor cell lines with HL-60, K562
and EM-3 showing higher NKp30L than NKp44L expression.
Primary PBMCs did not show any staining for NKp30L and
NKp44L (data not shown). This suggests that the NCR ligands are
less expressed in cell lines of hematological origin.
In some cases we observed relatively wide variations in NKp30L
and NKp44L expression when repeatedly staining the same cell line
(see MDA-435 in Fig. 3B or Shep in Fig. 4A). It was recently shown
thatNKcellshavetheabilitytosurveyspecificallycellsinmitosisand
that NCR are involved in this enhanced surveillance [18]. We
therefore investigated if the expression of NKp30L was cell cycle
regulated. We used colchicine or nocodazole to arrest cells in G2/M
phase (Fig. 5A). As a control we used DMSO or high concentrations
of colchicine for a short period of time to disrupt the microtubules
without arresting cells in G2/M. While these cells or DMSO treated
cells showed clearly detectable NKp30-ILZ staining, the expression
of NKp30L was reduced in cells arrested in G2/M phase after
colchicine (Fig. 5B)or nocodazole(Fig.5C)treatment. Similar results
were obtained for NKp44L expression and using Ig-fusion proteins
(data not shown). This demonstrates that NKp30L and NKp44L are
cell cycle-regulated, but that these ligands are actually down-
regulated during mitosis.
Figure 2. Detection of NKp30L and NKp44L on the surface of cells by FACS analysis. (A) 293T cells were analyzed without treatment (none) or after
incubation with medium or CS1-ILZ, followed by anti-ILZ mAb (ILZ-11) and PE-labeled goat anti-mouse IgG (GaM-PE) staining. (B, C) 293T cells were
stained with CS1-ILZ, NKp30-ILZ (B) or NKp44-ILZ (C) as described in (A) and analyzed by FACS. Mean fluorescence intensities of the stainings are
indicated in brackets.
doi:10.1371/journal.pone.0001339.g002
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first compared SD-1 cells showing no detectable NKp30L and
NKp44L expression with EM-3 cells, which showed good
expression of NKp30L and only weak expression of NKp44L
(Fig. 4B). When comparing the lysis of these two cell lines by IL-2-
activated primary NK cells from two different donors we detected
good lysis of EM-3 but weak lysis of SD-1 target cells, correlating
with the NCR ligand expression (Fig. 6A). More importantly, the
lysis of EM-3 cells could be reduced to the level of SD-1 killing by
using a blocking anti-NKp30 antibody, while this antibody did not
reduce the lysis of SD-1 cells (Fig. 6B). This again correlates with
the staining data for the expression of NKp30L on these two cell
lines. To check if the expression level of NKp30L correlates with
the NKp30-dependent lysis of tumor cells we tested K562 cells,
which showed detectable, but lower NKp30L expression com-
pared to EM-3 cells. Lysis of K562 cells could not be blocked by
anti-NKp30 nor by anti-NKp44 antibodies (Fig. 6C). This
demonstrates that a certain threshold of NKp30L expression is
necessary to induce significant NKp30-dependent lysis. To check if
the higher staining intensity for NKp44L on HeLa and Shep also
correlates with NKp44-mediated lysis we tested the NK cell-
mediated killing of these cells. Lysis of both cells could be blocked
by anti-NKp30 and anti-NKp44 antibodies (Fig. 6D, E). However,
the reduction mediated by blocking NKp30 was larger than the
reduction mediated by NKp44 blockade. This is in contrast to the
staining intensities in the FACS analysis (Fig. 4A).
The nature of NKp30L and NKp44L is still unclear. Recent
publications point towards an involvement of heparan sulfate
structures in the binding of NKp30 and NKp44. However, we
found that also protein structures are important for the binding of
NCR, as trypsin abolished the binding of NKp30-ILZ and
NKp44-ILZ to the surface of treated EM-3 cells (Fig. 7A). This
reduction in surface expression of NKp30L and NKp44L after
trypsin treatment also had functional consequences. Removal of
NKp30L from the surface of EM-3 cells significantly reduced the
lysis of these cells (Fig. 7B), which is largely dependent on the
engagement of NKp30 (Fig. 6B).
DISCUSSION
NCR are important activating receptors for the anti-tumor activity
of NK cells. However, only limited information exists about the




Panc-1 Pancreatic cancer cell line
Capan-1 Pancreatic cancer cell line
Su8686 Pancreatic cancer cell line
BXCP-3 Pancreatic cancer cell line
MiaPaCa Pancreatic cancer cell line
T3M4 Pancreatic cancer cell line
AsPc-1 Pancreatic cancer cell line
MCF7 Breast cancer cell line
BT-474 Breast cancer cell line
MDA-231 Breast cancer cell line
MDA-435 Breast cancer cell line
293T Embryonic kidney cell line
A125 Lung adenocarcinoma cell line
A549 Lung adenocarcinoma cell line
1106mel Melanoma cell line
HeLa Cervix carcinoma cell line
Shep Neuroblastoma cell line
Huh7 Hepatoma cell line
Colo201 Colon carcinoma cell line
Daudi Burkitt lymphoma cell line
Raji Burkitt lymphoma cell line
Namalwa Burkitt lymphoma cell line
K562 Chronic myeloid leukemia (CML) cell line
EM-3 Chronic myeloid leukemia (CML) cell line
THP-1 Acute monocytic leukemia (AML) cell line
HL-60 Acute monocytic leukemia (AML) cell line
721.221 EBV immortalized B cell line
SD-1 EBV immortalized acute lymphocytic leukemia (ALL) cell line
HFF Primary human foreskin fibroblasts


































































































































Figure 3. Analysis of NKp30L and NKp44L expression on pancreatic
carcinoma cell lines (A) and breast carcinoma cell lines (B). The
indicated cells were stained with CS1-ILZ, NKp30-ILZ or NKp44-ILZ and
analyzed by FACS. The mean fluorescence intensities (MFI) of the
NKp30-ILZ (black circles) and NKp44-ILZ (white circles) stainings were
divided by the MFI of CS1-ILZ background staining. Each dot represents
the result of an independent staining.
doi:10.1371/journal.pone.0001339.g003
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tumor cells [30,31]. Here we provided a more comprehensive
analysis of the expression of NKp30L and NKp44L. The surface
expression of NKp46L could not be analyzed, as our NKp46-ILZ
fusion protein did not give any significant surface staining on
several cells reported to express NKp46L. The second Ig domain
(D2) of NKp46 is essential for ligand recognition [30]. This
domain is directly adjacent to the ILZ sequence in our fusion
protein. One reason for the lack of NKp46-ILZ activity could be
the steric hindrance of the D2 domain by the ILZ sequence.
For NKp30L and NKp44L we found intracellular and
extracellular expression on almost all cell lines tested. Expression
of these ligands was not restricted to cell lines of any specific origin.
Instead, we found wide variations in NKp30L and NKp44L
surface expression among cell lines of the same histogenetic origin.
This is in agreement with an earlier study, which found variable
expression of NCR ligands in melanoma cells [15]. Interestingly,
we detected linked expression of NKp30L and NKp44L on many
cell lines derived from solid tumors. This is unlikely to be an
artifact or a cross-reactivity of our staining reagents as we did not
find such linked expression on cells of hematopoietic origin. The
different staining intensities of NKp30-ILZ and NKp44-ILZ could
either reflect a different expression of NKp30L and NKp44L, or
be simply the result of a higher affinity between NKp44L and the
NKp44 receptor. However, in the absence of an identified cellular
ligand for these receptors this questions cannot be answered.
Functionally, the higher staining intensity foe NKp44L does not
translate in higher NKp44-dependent lysis. To the contrary,
NKp30-dependent lysis was even higher than NKp44-dependent
lysis in the Shep and HeLa cell lines (Fig. 6). However, the staining
intensity for each ligand is indicative for the lysis. EM3 and K562
cells,showing lowstaining intensityfor NKp44Lwerenot lysed inan
NKp44-dependent fashion, whereas Shep and HeLa cells, showing
high staining intensity for NKp44L were lysed in a NKp44-
dependent way. Similarly, K562 cells, showing low NKp30L
staining intensity were not lysed in an NKp30-dependent fashion,
while EM-3, HeLa and Shep cells were. How much lysis of a given
target cell depends on NKp30 or NKp44 will also depend on the
expression of other activating NK cell ligands. Therefore, the
amountofNKp30LorNKp44Lstainingintensitycannotpredictthe
amount of NKp30 or NKp44-dependent NK cell lysis.
Heparan sulfate was reported to be involved in the recognition
of NCR, suggesting the recognition of similar ligands by these
receptors [27,28]. However, the differential expression of NKp30L
and NKp44L by the cell lines tested in this study suggests the
existence of distinct ligands for both receptors. Also, the stainings
of intracellular compartments with NKp46-Ig, NKp44-Ig and
NKp30-Ig revealed clearly different patterns, strongly suggesting
that these receptors recognize distinct target structures. The highly
reproducible and strong vesicular, intracellular stainings as
compared with the more variable surface stainings suggests that
the surface expression of NCR ligands may be regulated by plasma
membrane turnover. Changes in internalization rates might
provide tumor cells with a means to escape from NK cell attack.
The NCR ligands are likely to contain a protein component as
we found the surface expression of NKp30L and NKp44L to be
Figure 4. Analysis of NKp30L and NKp44L expression on solid tumor cell lines of different origin (A) and of cell lines hematopoietic origin (B).
The indicated cells were analyzed for NKp30L and NKp44L expression as described in figure 3.
doi:10.1371/journal.pone.0001339.g004
Analysis of NCR Ligands
PLoS ONE | www.plosone.org 5 December 2007 | Issue 12 | e1339sensitive to trypsin treatment. This has important implications for
the analysis of NCR ligand expression on adherent cells. To avoid
artifacts due the detachment of cells by trypsin we used a non-
enzymatic cell dissociation reagent in this study.
The increased surveillance of cells in mitosis by human NK cells
is blocked by hyaluronidase treatment and antibodies against
NKp46 or NKp44 [18]. As hyaluronan and NCR do not seem to
interact directly, NCR ligands could be higher expressed in mitotic
cells. Surprisingly, we found the opposite by demonstrating a clear
down-modulation of NKp30L and NKp44L on cells arrested in
mitosis. This suggests that the direct interaction between NCR and
their cellular ligands is not involved in the increased surveillance of
mitotic cells. Instead NCR might be important for the activation of
a hyaluronan-binding receptor.
Figure 5. Reduced expression of NKp30L in cells arrested in mitosis. (A) 293T cells were treated with DMSO for 18 hours, 10 mM colchicine (col) for
1 hour, 100 ng/ml nocodazole (noc) or 0.1 mM colchicine for 18 hours and the cell cycle stage of the treated cells was analyzed by FACS. Numbers
represent percentage of cells in G1 phase (left) S phase (middle) and G2/M phase (right). (B and C) the same cells as in (A) were analyzed for the
expression of NKp30L as described in Fig. 2.
doi:10.1371/journal.pone.0001339.g005
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hematopoietic system. Interestingly, we found the lowest expres-
sion of NKp30L and NKp44L on these cells, consistent with other
reports [31,33]. This could indicate that the NCR may not play a
major role in NK cell recognition of hematological disorders.
However, ligands for 2B4, CRACC and NTB-A are commonly
present on hematopoietic cells [8]. These receptors can effectively
co-stimulate NCR-mediated NK cell activation [34–36]. This co-
stimulation may provide sufficient NCR-mediated NK cell
activation even under conditions of low NCR ligand expression.
As these co-stimulatory ligands are missing in cell lines derived
from solid tumors, a higher expression of NCR ligands might be
necessary for efficient NK cell recognition.
MATERIALS AND METHODS
Cells and antibodies
C e l ll i n e su s e di nt h i ss t u d ya r el i s t e di nt a b l e s1a n d2 .P r i m a r y
human NK cells were isolated and cultured as described [37].
Antibodies used were MOPC-21 (Sigma) and phycoerythrine (PE)-
conjugated goat anti-mouse IgG (Jackson Immunoresearch, West
Grove, PA). Mouse anti-isoleucine-zipper (ILZ-11), mouse anti-
NKp30 (p30-15) and mouse anti-NKp44 (p44-8) monoclonal
antibodies were created in our laboratory by immunizing BALB/c
mice with the respective ILZ fusion protein. Specificity of the
resultinghybridomawasconfirmed usingELISAandflowcytometry.
Production of soluble fusion proteins and flow
cytometry staining
Isoleucin-zipper fusion proteins were produced as described
elsewhere [32]. Ig-fusion proteins were produced similarly [38]
but purified using protein A agarose Sepharose beads (Amersham)
and eluted with low pH glycin buffer. Resulting proteins were
dialyzed against PBS and analyzed for purity on a polyacrylamide
gel stained with Safestain (Invitrogen). For flow cytometry,
adherent cells were detached using enzyme free cell dissociation
buffer (Gibco). 1610
5 cells were resuspended in 50 ml staining
buffer (PBS/2% FCS) with 1 mg/ml of the respective ILZ fusion
protein. After 20 min on ice cells were washed and resuspended in
staining buffer with mouse anti-ILZ antibody (ILZ-11, 5 mg/ml)
and incubated for 20 min on ice. Then cells were washed again
and incubated with PE-conjugated goat anti-mouse antibody
(1:200) for 20 min on ice in the dark. Cells were washed and then
fixed with 2% formaldehyde in staining buffer and analyzed on a
Becton-Dickinson FACScan flow cytometer using the BD
Cellquest and FlowJo software.
Chromium release assay
Cytotoxicity assays were performed essentially as described [39].
Target cells (0.5610
6) were labeled in 100 ml assay medium (IMDM
with 10% FCS and 1% penicillin/streptomycin) with 100 mCi
(3.7 MBq) of
51Cr for 1 h at 37uC. Cells were washed twice and
resuspended at 5610
4 cells/ml in assay medium. Effector cells were
resuspended in assay medium and mixed at different effector to
target (E:T) ratios with 5000 labeled target cells/well in a 96-well V-
Figure 6. Correlation between NKp30L and NKp44L expression and
NKp30 and NKp44-mediated lysis by NK cells. (A) EM-3 and SD-1 cells
were used as targets in a 4 h
51Cr release assay using IL2-activated NK
cells from two different donors (NK1 and NK2) as effector cells at the
indicated effector to target (E/T) ratios. (B)
51Cr release assay of EM-3
and SD-1 target cells in the presence of control antibodies (cIgG1) or
blocking anti-NKp30 antibodies (aNKp30). (C–E) Lysis of K562 (C), HeLa
(D) and Shep (E) cells by IL-2 activated NK cells in the presence of
control antibodies (cIgG1) or blocking anti-NKp30 (aNKp30) and/or anti-
NKp44 antibodies (aNKp44).
doi:10.1371/journal.pone.0001339.g006
Figure 7. Surface expression of NKp30L and NKp44L is sensitive to Trypsin treatment. EM-3 cells were left untreated (control) or treated with
trypsin. (A) The expression of NKp30L and NKp44L was then analyzed as described in figure 3 or cells were used as targets in a
51Cr release assay (B).
doi:10.1371/journal.pone.0001339.g007
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cells were preincubated with the respective antibodies (10 mg/ml
final concentration) for 15 min at 37uC before addition of target
cells. Maximum release was determined by incubation of target cells
in 1% Triton X-100 solution. For spontaneous release, targets were
incubated without effectors in assay medium alone. All samples were
done in triplicates. Plates were incubated for 4 h at 37uC.
Supernatant was harvested and
51Cr-release was measured in a c-
counter. Percent specific release was calculated as ([experimental
release2spontaneous release]/[maximum release2spontaneous re-
lease])6100. The ratio between maximum and spontaneous release
was at least 3 in all experiments.
Trypsin treatment, cell cycle arrest and analysis
For trypsin treatment cells were washed once with PBS and
incubated in trypsin solution (0.25 %) for 10 minutes at 37uC. The
incubation was stopped by washing the cells once in FCS
containing medium and cells were analyzed immediately.
293T cells were seeded in 6-well plates at a density of 0.5610
6
cells/well. For cell cycle inhibition cells were treated for 18 hours
either with 0.1 mM colchicine or 100 ng/ml nocodazole. DMSO
was used as a control. As an additional control cells were treated
with 10 mM colchizine for 1 hour directly before fixation.
Afterwards, cells were harvested and washed with 1 ml of PBS/
0.5% FCS. Then cells were resuspended in 50 ml PBS/0.5% FCS
and fixed with 150 ml ice-cold ethanol and stored at 220uC for at
least 48 h. Then cells were washed three times using PBS/0.5%
FCS and afterwards resuspended in 300 ml propidium iodide
staining solution (20 mg/ml PI, 100 mg/ml RNase, 0.1% Triton
X-100) and incubated for 30 min at room temperature. Cells were
analyzed using a BD FACSCalibur.
Staining of cytospins
Cytospins were prepared by centrifuging ,1610
5 tumor cells per
sample onto glass slides using a Shandon Cytospin 2. Cells were
air-dried over night and then fixed in acetone for 10 min at room
temperature. Following rehydration in PBS, cell spots were
incubated with ,1 mg purified NKp46-Ig, NKp44-Ig or
NKp30-Ig in 50 ml PBS/2% FCS for 45 min at room tempera-
ture. After washing of the slides with PBS, cells were incubated
with peroxidase-conjugated goat anti-human IgG-Fc (Dianova,
Hamburg, Germany) (dilution 1:200 in PBS/2% FCS) for 30 min
at room temperature. The peroxidase was developed using
0.4 mg/ml 3-amino-9-ethylcarbazole (Sigma-Aldrich, Tauf-
kirchen, Germany) in 0.1 M Na acetate buffer (pH 5.2) and
0.015% H2O2. Monoclonal antibodies recognizing the cellular
compartment markers calnexin, GM130, EEA-1 and LAMP-1
were from Becton Dickinson (Heidelberg, Germany). These
antibodies were diluted 1:50 in 50 ml PBS/2% FCS per slide
and after binding for 45 min reacted with goat anti-mouse (or rat)
IgG-Fc (Dianova, Hamburg, Germany). Slides were mounted in
glycerol gelatine (Merck, Darmstadt, Germany). Cells were
analyzed using an Olympus BH-2 microscope.
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